Balchem FY26 Q2 net earnings rise 16.6% to $44.6 million; net sales increase 11.2% to $284 million

• Balchem posted Q2 2026 GAAP net earnings of USD 44.6 million, up 16.6% year over year, as net sales rose 11.2% to USD 284 million.
• GAAP EPS increased to USD 1.39 from USD 1.17 a year earlier; adjusted EPS rose to USD 1.49 from USD 1.27.
• Adjusted EBITDA climbed 12.6% year over year to USD 77.9 million; cash from operations was USD 46.7 million, with free cash flow of USD 36.2 million.
• Human Nutrition and Health net sales grew 10% to USD 176.9 million, while Animal Nutrition and Health climbed 15% to USD 64.5 million.
• Extended its senior secured revolving credit facility maturity to July 2031, raising borrowing capacity to USD 650 million; repurchased USD 29 million of stock in Q2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Balchem Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607310700PRIMZONEFULLFEED9801456) on July 31, 2026, and is solely responsible for the information contained therein.